Table 1 Baseline and TB-IRIS characteristics of the 212 patients included in Cox proportional hazards model
Variable | Median (interquartile range) or number (%) |
|---|---|
Gender (n = 212) | |
 Female | 138 (65.1 %) |
 Male | 74 (34.9 %) |
Age (years) (n = 212) | 31 (27, 36) |
WHO stage (n = 212) | |
 3 | 71 (33.5 %) |
 4 | 141 (66.5 %) |
CD4 count prior to ART (cells/μl) (n = 199) | 52 (28, 92.5) |
CD4 count at TB-IRIS (cells/μl) (n = 95) | 116 (71, 209.5) |
Previous TB (n = 211) | 55 (25.9 %) |
Drug-resistant TB (n = 212)a | 21 (10 %) |
Initial TB diagnosis with extra-pulmonary involvement (n = 212) | 134 (63.2 %) |
Initial TB diagnosis with lymph node involvement (n = 212) | 50 (23.6 %) |
Duration from TB treatment to ART (days) (n = 211) | 56 (31, 83) |
Duration from ART to TB-IRIS onset (days) (n = 211) | 14 (7, 21) |
Hospitalised at time of TB-IRIS diagnosis (n = 206) | 107 (50.5 %) |
TB-IRIS lymph node involvement (n = 212) | 80 (37.7 %) |
TB-IRIS pulmonary involvement (n = 212) | 83 (39.2 %) |
TB-IRIS meningitis (n = 209) | 10 (4.7 %) |
TB-IRIS abdominal involvement (n = 212) | 154 (72.6 %) |
TB-IRIS multisystem involvement (n = 212) | 166 (78.3 %) |
Pulse rate (n = 134) | 120 (107.3, 132) |
C-reactive protein (mg/l) (n = 195) | 103 (63, 158.5) |
Haemoglobin (g/dl) (n = 136) | 9.1 (8, 10.4) |
White cell count (× 109/l) (n = 132) | 5.7 (4.1, 8.1) |
ALT (IU/l) (n = 180) | 34 (22, 51) |
Alkaline phosphatase (IU/l) (n = 164) | 159 (107, 274.8) |
Corticosteroid treatment for TB-IRIS | 125 (59.0Â %) |